Cargando…

Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years

BACKGROUND: Women with SLE have higher rates of persistent human papilloma virus (HPV) infections and precancerous lesions than healthy women. HPV vaccine is safe and effective in healthy females aged 9–26 years. There are limited data on the safety and immunogenicity of HPV vaccine in females with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soybilgic, Arzu, Onel, Karen B, Utset, Tammy, Alexander, Kenneth, Wagner-Weiner, Linda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751269/ https://www.ncbi.nlm.nih.gov/pubmed/23924237 http://dx.doi.org/10.1186/1546-0096-11-29

Ejemplares similares

A survey of steroid-related osteoporosis diagnosis, prevention and treatment practices of pediatric rheumatologists in North America
por: Soybilgic, Arzu, et al.
Publicado: (2014)

Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus
por: Utset, Tammy O, et al.
Publicado: (2015)

The effect of history of abnormal pap smear or preceding HPV infection on the humoral immune response to Quadrivalent Human Papilloma virus (qHPV) vaccine in women with systemic lupus erythematosus
por: Dhar, J. Patricia, et al.
Publicado: (2018)

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years
por: Maldonado, Ivette, et al.
Publicado: (2022)

Osteopontin Alleles Are Associated with Clinical Characteristics in Systemic Lupus Erythematosus
por: Trivedi, Tarak, et al.
Publicado: (2011)

Perceptions of racism in healthcare among patients with systemic lupus erythematosus: a cross-sectional study
por: Vina, Ernest R, et al.
Publicado: (2015)

Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study
por: Sankaranarayanan, Rengaswamy, et al.
Publicado: (2016)

Ongoing inadequacy of quadrivalent HPV vaccine safety studies
por: Little, Deirdre T, et al.
Publicado: (2020)

Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal ≥ HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2021)

A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination
por: Batmunkh, Tsetsegsaihan, et al.
Publicado: (2020)

Bullous systemic lupus erythematosus in females
por: Sprow, Grant, et al.
Publicado: (2022)

Contraception for adolescents with lupus
por: Tesher, Melissa S, et al.
Publicado: (2010)

Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM)
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2017)

Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus
por: Bhattacharya, Jyotsna, et al.
Publicado: (2018)

Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis
por: Tjon Pian Gi, Robin E. A., et al.
Publicado: (2016)

Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2017)

Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Gene-Expression-Guided Selection of Candidate Loci and Molecular Phenotype Analyses Enhance Genetic Discovery in Systemic Lupus Erythematosus
por: Koldobskaya, Yelena, et al.
Publicado: (2012)

L1 Recombinant Proteins of HPV Tested for Antibody Forming Using Sera of HPV Quadrivalent Vaccine
por: Akuzum, Begum, et al.
Publicado: (2018)

Effectiveness of quadrivalent HPV vaccination in reducing vaccine-type and nonvaccine-type high risk HPV infection
por: Li, Chenxi, et al.
Publicado: (2023)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
por: Sow, Samba O., et al.
Publicado: (2023)

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
por: Moreira, E. D., et al.
Publicado: (2017)

Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus
por: Kariuki, Silvia N, et al.
Publicado: (2010)

A study of racial/ethnic differences in treatment preferences among lupus patients
por: Vina, Ernest R., et al.
Publicado: (2012)

The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia
por: Uusküla, Anneli, et al.
Publicado: (2013)

Correction: Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2018)

The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis
por: Lukács, Anita, et al.
Publicado: (2020)

Early Direct and Indirect Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts: a Systematic Review
por: Mariani, Luciano, et al.
Publicado: (2015)

Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
por: Gee, Julianne, et al.
Publicado: (2016)

Systemic lupus erythematosus presenting as acute lupus pneumonitis in a young female
por: Chattopadhyay, B, et al.
Publicado: (2015)

Lupus Cerebritis as the Initial Presentation of Systemic Lupus Erythematosus in a Young Female
por: Gosal, Kiranpreet, et al.
Publicado: (2021)

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age
por: Castellsagué, X, et al.
Publicado: (2011)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination
por: Östensson, Ellinor, et al.
Publicado: (2015)

Human Papillomavirus (HPV) and the quadrivalent HPV Vaccine among Brazilian adolescents and parents: Factors associated with and divergences in knowledge and acceptance
por: Gomes, Jéssica Menezes, et al.
Publicado: (2020)

Incidence of anogenital warts after the introduction of the quadrivalent HPV vaccine program in Manitoba, Canada
por: Righolt, Christiaan H., et al.
Publicado: (2022)

Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy
por: Shirai, Shimpei, et al.
Publicado: (2018)

Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older
por: Greenberg, David P., et al.
Publicado: (2017)

Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season
por: Jagielska, Anna M., et al.
Publicado: (2021)

Erratum: Systemic lupus erythematosus presenting as acute lupus pneumonitis in a young female
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2s2sq63njfp9454dfok6boabtg